Gladius Capital Management LP Athira Pharma, Inc. Transaction History

Gladius Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 Dec 18, 2023	BUY	$2.26 - $4.22 $19,266 - $35,975	8,525 New	8,525 $21,000
Q1 2023 May 09, 2023	SELL	$2.26 - $4.22 $7,392 - $13,803	-3,271 Reduced 27.73%	8,525 $22,000
Q4 2022 Dec 18, 2023	BUY	$2.76 - $3.71 $32,556 - $43,763	11,796 New	11,796 $37,000
Q4 2022 Feb 02, 2023	BUY	$2.76 - $3.71 $1,639 - $2,203	594 Added 5.3%	11,796 $38,000
Q3 2022 Nov 14, 2022	BUY	$2.93 - $3.96 $32,821 - $44,359	11,202 New	11,202 $34,000

16.9M

112K

68K

Ticker ATHA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 37,817,700
Market Cap $21.9M
Description
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...

Get notified when there are updates to the investment portfolio of Gladius Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Gladius Capital Management LP with notifications on news.